Delcath Systems Inc (DCTH)

$9.67

-0.78

(-7.46%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $9.53
    $10.42
    $9.67
    downward going graph

    1.45%

    Downside

    Day's Volatility :8.54%

    Upside

    7.2%

    downward going graph
  • $2.25
    $11.75
    $9.67
    downward going graph

    76.73%

    Downside

    52 Weeks Volatility :80.84%

    Upside

    17.67%

    downward going graph

Returns

PeriodDelcath Systems IncIndex (Russel 2000)
3 Months
47.63%
0.0%
6 Months
142.36%
0.0%
1 Year
110.22%
0.0%
3 Years
-6.84%
-22.3%

Highlights

Market Capitalization
270.8M
Book Value
$0.15
Earnings Per Share (EPS)
-2.52
Wall Street Target Price
21.33
Profit Margin
0.0%
Operating Margin TTM
-50.37%
Return On Assets TTM
-81.99%
Return On Equity TTM
-478.59%
Revenue TTM
11.9M
Revenue Per Share TTM
0.51
Quarterly Revenue Growth YOY
1468.9%
Gross Profit TTM
2.0M
EBITDA
-35.9M
Diluted Eps TTM
-2.52
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.34
EPS Estimate Next Year
-0.25
EPS Estimate Current Quarter
-0.36
EPS Estimate Next Quarter
-0.31

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Delcath Systems Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 120.58%

Current $9.67
Target $21.33

Company Financials

FY18Y/Y Change
Revenue
3.4M
↑ 25.49%
Net Income
-19.2M
↓ 57.4%
Net Profit Margin
-564.19%
↑ 1097.58%
FY19Y/Y Change
Revenue
1.6M
↓ 53.62%
Net Income
-13.6M
↓ 29.11%
Net Profit Margin
-862.47%
↓ 298.28%
FY20Y/Y Change
Revenue
1.6M
↑ 4.18%
Net Income
-24.5M
↑ 79.68%
Net Profit Margin
-1.5K%
↓ 625.08%
FY21Y/Y Change
Revenue
3.6M
↑ 115.98%
Net Income
-26.8M
↑ 9.28%
Net Profit Margin
-752.66%
↑ 734.89%
FY22Y/Y Change
Revenue
2.7M
↓ 23.52%
Net Income
-39.2M
↑ 46.37%
Net Profit Margin
-1.4K%
↓ 687.69%
FY23Y/Y Change
Revenue
2.1M
↓ 24.05%
Net Income
-47.7M
↑ 21.74%
Net Profit Margin
-2.3K%
↓ 868.51%
Q1 FY23Q/Q Change
Revenue
597.0K
↓ 6.57%
Net Income
-10.4M
↓ 14.31%
Net Profit Margin
-1.7K%
↑ 156.79%
Q2 FY23Q/Q Change
Revenue
495.0K
↓ 17.09%
Net Income
-7.2M
↓ 30.5%
Net Profit Margin
-1.5K%
↑ 280.9%
Q3 FY23Q/Q Change
Revenue
434.0K
↓ 12.32%
Net Income
-20.3M
↑ 182.42%
Net Profit Margin
-4.7K%
↓ 3231.69%
Q4 FY23Q/Q Change
Revenue
539.0K
↑ 24.19%
Net Income
-11.1M
↓ 45.25%
Net Profit Margin
-2.1K%
↑ 2620.59%
Q1 FY24Q/Q Change
Revenue
3.1M
↑ 482.37%
Net Income
-11.1M
↓ 0.22%
Net Profit Margin
-353.97%
↑ 1712.08%
Q2 FY24Q/Q Change
Revenue
7.8M
↑ 147.4%
Net Income
-13.7M
↑ 23.67%
Net Profit Margin
-176.94%
↑ 177.03%
FY18Y/Y Change
Total Assets
6.8M
↓ 22.99%
Total Liabilities
21.8M
↑ 165.36%
FY19Y/Y Change
Total Assets
14.2M
↑ 107.66%
Total Liabilities
20.6M
↓ 5.57%
FY20Y/Y Change
Total Assets
34.6M
↑ 143.7%
Total Liabilities
12.6M
↓ 38.95%
FY21Y/Y Change
Total Assets
33.1M
↓ 4.36%
Total Liabilities
21.2M
↑ 68.61%
FY22Y/Y Change
Total Assets
17.9M
↓ 46.08%
Total Liabilities
23.7M
↑ 12.04%
FY23Y/Y Change
Total Assets
38.6M
↑ 116.17%
Total Liabilities
22.8M
↓ 3.73%
Q1 FY23Q/Q Change
Total Assets
30.6M
↑ 71.31%
Total Liabilities
43.7M
↑ 84.12%
Q2 FY23Q/Q Change
Total Assets
21.1M
↓ 31.21%
Total Liabilities
21.3M
↓ 51.25%
Q3 FY23Q/Q Change
Total Assets
47.6M
↑ 126.02%
Total Liabilities
22.9M
↑ 7.35%
Q4 FY23Q/Q Change
Total Assets
38.6M
↓ 18.84%
Total Liabilities
22.8M
↓ 0.1%
Q1 FY24Q/Q Change
Total Assets
36.1M
↓ 6.51%
Total Liabilities
21.5M
↓ 5.94%
Q2 FY24Q/Q Change
Total Assets
33.9M
↓ 6.06%
Total Liabilities
29.7M
↑ 38.37%
FY18Y/Y Change
Operating Cash Flow
-14.7M
↓ 4.33%
Investing Cash Flow
-76.0K
↓ 85.5%
Financing Cash Flow
13.2M
↓ 14.3%
FY19Y/Y Change
Operating Cash Flow
-23.7M
↑ 60.81%
Investing Cash Flow
-24.0K
↓ 68.42%
Financing Cash Flow
30.3M
↑ 128.96%
FY20Y/Y Change
Operating Cash Flow
-22.9M
↓ 3.47%
Investing Cash Flow
-782.0K
↑ 3158.33%
Financing Cash Flow
42.4M
↑ 39.76%
FY21Y/Y Change
Operating Cash Flow
-22.6M
↓ 1.15%
Investing Cash Flow
-143.0K
↓ 81.71%
Financing Cash Flow
20.8M
↓ 50.84%
FY22Y/Y Change
Operating Cash Flow
-25.0M
↑ 10.38%
Investing Cash Flow
-209.0K
↑ 46.15%
Financing Cash Flow
10.1M
↓ 51.29%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.3M
↓ 42.06%
Investing Cash Flow
-40.0K
↑ 0.0%
Financing Cash Flow
16.7M
↑ 218.16%
Q2 FY23Q/Q Change
Operating Cash Flow
-9.6M
↑ 126.27%
Investing Cash Flow
-40.0K
↑ 0.0%
Financing Cash Flow
7.0K
↓ 99.96%

Technicals Summary

Sell

Neutral

Buy

Delcath Systems Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Delcath Systems Inc
Delcath Systems Inc
24.13%
142.36%
110.22%
-6.84%
26.24%
Stryker Corporation
Stryker Corporation
12.3%
0.36%
24.19%
28.8%
65.26%
Boston Scientific Corp.
Boston Scientific Corp.
10.6%
20.32%
51.42%
80.93%
95.5%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
9.4%
-28.78%
-12.2%
-45.23%
-7.73%
Abbott Laboratories
Abbott Laboratories
3.57%
-5.84%
13.1%
-11.32%
35.19%
Medtronic Plc
Medtronic Plc
10.85%
5.57%
12.46%
-33.2%
-16.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Delcath Systems Inc
Delcath Systems Inc
NA
NA
NA
-1.34
-4.79
-0.82
NA
0.15
Stryker Corporation
Stryker Corporation
39.84
39.84
2.64
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
66.34
66.34
2.01
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.3
26.3
3.2
2.69
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.92
35.92
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.16
30.16
1.66
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Delcath Systems Inc
Delcath Systems Inc
Buy
$270.8M
26.24%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$136.8B
65.26%
39.84
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$120.2B
95.5%
66.34
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.2B
-7.73%
26.3
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.1B
35.19%
35.92
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.3B
-16.71%
30.16
12.06%

Insights on Delcath Systems Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 434.0K → 7.76M (in $), with an average increase of 54.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -11.11M → -13.74M (in $), with an average decrease of 23.7% per quarter

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 87.7%

Institutional Holdings

  • Rosalind Advisors, Inc.

    9.47%

  • AIGH Capital Management, LLC

    8.57%

  • Vivo Capital, LLC

    5.95%

  • Bvf Inc

    4.29%

  • Vanguard Group Inc

    3.56%

  • Essex Investment Management Company, LLC

    1.20%

Company Information

delcath systems, inc. (nasdaq- dcth) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. our proprietary product---melphalan hydrochloride for injection for use with the delcath hepatic delivery system (melphalan/hds)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. delcath is in late-stage clinical development in the united states with initial commercial activities in europe, where the melphalan/hds is marketed as a ce marked device under the trade name delcath hepatic chemosat® delivery system for melphalan (chemosat). our commercial strategy for chemosat is to steadily grow clinical adoption in major european markets and utilize physician experience to support appeals for reimbursement. since launch over 250 chemosat treatments have been performed at over 20 leading european cancer centers. in 2016, we launched our focus pivotal study in hepatic dominant ocular

Organization
Delcath Systems Inc
Employees
76
CEO
Mr. Gerard J. Michel MBA, MS
Industry
Medical Specialties

Discover More

FAQs